3月29日,英硅智能公布了港股上市后的首份年报。紧随其后,英硅智能宣布与礼来达成27.5亿美元合作。 根据协议,礼来将获得一项全球独家许可,用于开发、生产和商业化针对特定适应症、目前处于临床前开发阶段的、具有潜在“同类最佳”水平的新型口服治疗药物。此外,英硅智能与礼来还将围绕礼来选定的靶点开展多项研发项目合作。协议条款显示,英硅智能将有资格获得1.15亿美元首付款,并在后续达成开发、监管及商业化...
Source Link3月29日,英硅智能公布了港股上市后的首份年报。紧随其后,英硅智能宣布与礼来达成27.5亿美元合作。 根据协议,礼来将获得一项全球独家许可,用于开发、生产和商业化针对特定适应症、目前处于临床前开发阶段的、具有潜在“同类最佳”水平的新型口服治疗药物。此外,英硅智能与礼来还将围绕礼来选定的靶点开展多项研发项目合作。协议条款显示,英硅智能将有资格获得1.15亿美元首付款,并在后续达成开发、监管及商业化...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.